Downregulating the p38MAPK signaling pathway improves dyslipidemia and phlegm-turbidity obstruction syndrome by reducing the transcription levels of ICAM and E-Selectin genes and decreasing oxidative stress. Here, SELE is linked to metabolic syndrome.